The prospect of slowing Alzheimer's progression through targeted amyloid removal has moved from theoretical possibility to clinical reality, with implications extending far beyond Western populations where most trials occur. Real-world evidence now demonstrates meaningful therapeutic impact across diverse genetic backgrounds.
This multicenter analysis of 261 Chinese patients receiving lecanemab infusions showed significant cognitive preservation compared to matched controls, with brain amyloid plaques decreasing by an average of 22.1 Centiloid units over six months. Nearly 30% of patients achieved amyloid-negative status on PET scans. Plasma phosphorylated tau-217 levels correlated directly with plaque clearance, suggesting this blood marker could replace expensive brain imaging for monitoring treatment response. Patients without APOE ε4 genetic variants experienced superior outcomes, confirming genetic factors influence therapeutic efficacy.
These findings validate amyloid-targeting strategies across ethnic populations while revealing practical monitoring approaches that could democratize access to precision dementia care. The study's real-world design—conducted across 21 clinical sites rather than controlled research environments—provides stronger evidence for everyday clinical effectiveness than traditional trials. However, the six-month timeframe limits conclusions about long-term cognitive benefits, and the 9.2% rate of brain swelling side effects, while manageable, requires careful patient selection and monitoring. Most critically, this represents confirmatory rather than breakthrough science—lecanemab's modest cognitive benefits were established in previous studies, though the plasma biomarker findings offer genuinely novel clinical utility. For health-conscious adults with family dementia history, these results suggest genetic testing and early biomarker monitoring may soon guide preventive interventions.